Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma

Abstract

Squamous cell carcinoma of the prostate is a rare tumor. It has been typically described as an aggressive cancer, with a median survival time of 14 months. We present a case of locally advanced squamous cell carcinoma of the prostate with a regional lymph node metastasis. The patient received a novel combination chemotherapy regimen, docetaxel, cisplatin, and 5-fluorouracil, with radiotherapy to the whole pelvis and prostate. He was subsequently treated with seven courses of docetaxel, cisplatin, and 5-fluorouracil chemotherapy without any severe adverse events. We identified a 60.1 % reduction in the prostatic tumor, and the lymph node metastasis was shrunk after chemotherapy. A needle biopsy of the prostate after chemotherapy revealed no malignancy. No recurrence has been observed for 24 months. A combination of docetaxel, cisplatin, and 5-fluorouracil chemotherapy and radiotherapy might be an effective therapy for squamous cell carcinoma of the prostate.

Keywords: Cisplatin; Docetaxel; Fluorouracil; Prostate; Squamous cell carcinoma.

Fig. 1

Histological finding of the prostate tissue revealed well-differentiated squamous cell carcinoma with intracytoplasmic keratinization, clearly defined intercellular bridges (a), and individual keratinization (b). Hematoxylin and eosin stain

Fig. 2

Pelvic CT image showed an irregularly enlarged prostate, compressing the base of the bladder and disrupting the prostatic anatomy before therapy (a). After seven cycles of DCF chemotherapy with radiotherapy, the prostate tumor had shrunk (b)

Fig. 3

Enlarged lymph node of the left obturator nerve was detected before chemo-radiotherapy (a). Significant reduction of the lymph node was observed after chemo-radiotherapy (b)